FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904351479> ?p ?o ?g. }

• W2904351479 endingPage "100212" @default.
• W2904351479 startingPage "100212" @default.
• W2904351479 abstract "Bone metastases (BMs) are common in patients with prostate cancer and can lead to skeletal-related events (SREs), which are associated with increased pain and reduced quality of life (QoL). Bone-targeted agents (BTAs), such as zoledronic acid and denosumab, reduce the incidence of SREs and delay progression of bone pain.We evaluated the management of BMs and pain in six European countries (Belgium, France, Germany, Italy, Spain and the UK) using the Adelphi Prostate Cancer Disease Specific Programme. Patient-reported outcomes (PROs) were used to assess the impact of BMs on pain and QoL.In total, 358 physicians completed Patient Record Forms, of whom 246 were oncologists and 112 were urologists. Data were collected on 3667 patients with prostate cancer, including 1971 with BMs and 551 with metastases at sites other than bone (non-BMs). PROs were assessed in 573 patients with BMs and 220 with non-BMs. Most patients with BMs (74%) received a BTA and 53% received treatment within 3 months of BM diagnosis. Patients treated by oncologists were more likely than those treated by urologists to receive a BTA (78% vs. 60%) and to have treatment initiated within 3 months of BM diagnosis (56% vs. 43%). For patients who did not receive a BTA, the main reasons for not treating were very recent BM diagnosis and a perceived low risk of bone complications. Data collected by physicians showed that most patients with BMs (97%) were taking analgesics, with 30% receiving strong opioids. Despite this, 70% were currently experiencing bone pain and 28% were experiencing moderate to severe pain. PRO pain measures showed that 70% of patients with BMs were experiencing moderate to extreme pain, suggesting a disparity between pain levels reported by physicians and by patients.Although most patients with BMs receive a BTA, there remain a proportion of patients who are not receiving adequate treatment to prevent SREs or manage pain. Oncologists are more likely to adhere to clinical guidelines than urologists for the prescription of BTAs. Bone pain is common and undertreated. Increasing awareness of SRE prevention and bone pain management might improve patient care." @default.
• W2904351479 created "2018-12-22" @default.
• W2904351479 creator A5001154948 @default.
• W2904351479 creator A5009015905 @default.
• W2904351479 creator A5025804381 @default.
• W2904351479 creator A5050178081 @default.
• W2904351479 creator A5053293171 @default.
• W2904351479 creator A5065009288 @default.
• W2904351479 creator A5068746768 @default.
• W2904351479 creator A5088327914 @default.
• W2904351479 date "2019-02-01" @default.
• W2904351479 modified "2023-10-17" @default.
• W2904351479 title "A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in Europe" @default.
• W2904351479 cites W1549522748 @default.
• W2904351479 cites W1564144846 @default.
• W2904351479 cites W1814843139 @default.
• W2904351479 cites W1907547957 @default.
• W2904351479 cites W1975577875 @default.
• W2904351479 cites W1986064336 @default.
• W2904351479 cites W2004909463 @default.
• W2904351479 cites W2014574900 @default.
• W2904351479 cites W2026764315 @default.
• W2904351479 cites W2027188051 @default.
• W2904351479 cites W2028387248 @default.
• W2904351479 cites W2035309228 @default.
• W2904351479 cites W2039962951 @default.
• W2904351479 cites W2071300290 @default.
• W2904351479 cites W2072518464 @default.
• W2904351479 cites W2096382053 @default.
• W2904351479 cites W2104923745 @default.
• W2904351479 cites W2108802610 @default.
• W2904351479 cites W2110707581 @default.
• W2904351479 cites W2131952914 @default.
• W2904351479 cites W2135876989 @default.
• W2904351479 cites W2137458001 @default.
• W2904351479 cites W2138246663 @default.
• W2904351479 cites W2138809580 @default.
• W2904351479 cites W2139860898 @default.
• W2904351479 cites W2141454098 @default.
• W2904351479 cites W2146526476 @default.
• W2904351479 cites W2153528246 @default.
• W2904351479 cites W2161824335 @default.
• W2904351479 cites W2170731023 @default.
• W2904351479 cites W2273347348 @default.
• W2904351479 cites W2329099948 @default.
• W2904351479 cites W2339758831 @default.
• W2904351479 cites W2473786944 @default.
• W2904351479 cites W2517885389 @default.
• W2904351479 cites W2548191924 @default.
• W2904351479 cites W2599238962 @default.
• W2904351479 cites W2607028219 @default.
• W2904351479 cites W4245726844 @default.
• W2904351479 cites W4252377846 @default.
• W2904351479 cites W4322702919 @default.
• W2904351479 doi "https://doi.org/10.1016/j.jbo.2018.100212" @default.
• W2904351479 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6319023" @default.
• W2904351479 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30627511" @default.
• W2904351479 hasPublicationYear "2019" @default.
• W2904351479 type Work @default.
• W2904351479 sameAs 2904351479 @default.
• W2904351479 citedByCount "22" @default.
• W2904351479 countsByYear W29043514792019 @default.
• W2904351479 countsByYear W29043514792020 @default.
• W2904351479 countsByYear W29043514792021 @default.
• W2904351479 countsByYear W29043514792022 @default.
• W2904351479 countsByYear W29043514792023 @default.
• W2904351479 crossrefType "journal-article" @default.
• W2904351479 hasAuthorship W2904351479A5001154948 @default.
• W2904351479 hasAuthorship W2904351479A5009015905 @default.
• W2904351479 hasAuthorship W2904351479A5025804381 @default.
• W2904351479 hasAuthorship W2904351479A5050178081 @default.
• W2904351479 hasAuthorship W2904351479A5053293171 @default.
• W2904351479 hasAuthorship W2904351479A5065009288 @default.
• W2904351479 hasAuthorship W2904351479A5068746768 @default.
• W2904351479 hasAuthorship W2904351479A5088327914 @default.
• W2904351479 hasBestOaLocation W29043514791 @default.
• W2904351479 hasConcept C120665830 @default.
• W2904351479 hasConcept C121332964 @default.
• W2904351479 hasConcept C121608353 @default.
• W2904351479 hasConcept C126322002 @default.
• W2904351479 hasConcept C143998085 @default.
• W2904351479 hasConcept C159110408 @default.
• W2904351479 hasConcept C2776139714 @default.
• W2904351479 hasConcept C2776286101 @default.
• W2904351479 hasConcept C2776326535 @default.
• W2904351479 hasConcept C2776541429 @default.
• W2904351479 hasConcept C2779951463 @default.
• W2904351479 hasConcept C2780192828 @default.
• W2904351479 hasConcept C61511704 @default.
• W2904351479 hasConcept C71924100 @default.
• W2904351479 hasConceptScore W2904351479C120665830 @default.
• W2904351479 hasConceptScore W2904351479C121332964 @default.
• W2904351479 hasConceptScore W2904351479C121608353 @default.
• W2904351479 hasConceptScore W2904351479C126322002 @default.
• W2904351479 hasConceptScore W2904351479C143998085 @default.
• W2904351479 hasConceptScore W2904351479C159110408 @default.
• W2904351479 hasConceptScore W2904351479C2776139714 @default.
• W2904351479 hasConceptScore W2904351479C2776286101 @default.

• next